Summary
1. The seizure threshold of mice was determined by means of timed i.v. infusion of Pentamethylenetetrazol (Metrazol, Cardiazol), after changing the Serotonin content of the brain by pretreatment with Reserpine, which is known to liberate Serotonin, an inhibitor of amineoxydase activity Iproniazid (IPN), and the precursor of Serotonin 5-Hydroxytryptophan (5-HTP).
2. The facilitation of the tonic extensor seizure response by 5 mg/kg Reserpine was prevented by the previous injection of 100 mg/kg IPN; moreover, after this pretreatment a higher average dose of Metrazol was required to produce extensor seizures, as in controls.
3. IPN 100 mg/kg produced no change of the seizure threshold. A small elevation of the threshold for tonic convulsions was observed after treatment with 50 mg/kg 5-HTP. When the animals were pretreated with IPN, the injection of 5-HTP exerted a distinct elevation of the threshold for tonic convulsions. The same threshold elevation followed the injection of 50 mg/kg Dihydroxyphenylalanin (DOPA) after pretreatment with IPN, while DOPA alone was ineffective.
4. When amine-oxydase activity is inhibited by IPN, an increase of spontaneous activity is exerted by 5-HTP, DOPA and Reserpine. This action, produced by excess of liberated amines, is considered to be related with the observed elevation of threshold for tonic seizures.
Similar content being viewed by others
Literatur
Biehler, W.: Allg. Z. Psychiat. 116, 316 (1940).
Blaschko, H.: J. Physiol. (Lond.) 101, 337 (1942).
Bonnycastle, D. D., N. J. Giarman and M. K. Paasonen: Brit. J. Pharmacol. 12, 228 (1957).
Bonnycastle, D. D., M. K. Paasonen and N. J. Giarman: Fed. Proc. 16, 284 (1957).
Brodie, B. B., J. S. Olin, R. G. Kuntzman and P. A. Shore: Science 1957, 1293.
Brodie, B. B., A. Pletscher and P. A. Shore: J. Pharmacol. exp. Ther. 116, 9 (1956).
Brücke, F., W. Kobinger, O. Kraupp u. B. Pillat: Biochem. Z. 328, 56 (1956).
Chen, G., and B. Bohner: Fed. Proc. 15, 408 (1956).
Chen, G., and B. Bohner: J. Pharmacol. exp. Ther. 119, 559 (1957).
Chen, G., B. Bohner and C. R. Ensor: Proc. Soc. exp. Biol. (N. Y.) 87, 334 (1954).
Chen, G., and C. R. Ensor: Proc. Soc. exp. Biol. (N. Y.) 87, 602 (1954).
Chen, G., C. R. Ensor and B. Bohner: Proc. Soc. exp. Biol. (N. Y.) 86, 507 (1954).
Chessin, M., E. R. Kramer and C. Scott: J. Pharmacol. exp. Ther. 119, 453 (1957).
Euler, U. S., v., and P. Udden: Experientia (Basel) 7, 465 (1951).
Holtz, P., H. Balzer, E. Westermann u. E. Wezler: Naunyn-Schmiedeberg's Arch. exp. Path. Pharmak. 231, 333 (1957).
Holtz, P., K. Credner u. W. Koepp: Naunyn-Schmiedeberg's Arch. exp. Path. Pharmak. 200, 356 (1942).
Holtz, P., R. Heise u. K. Lüdtke: Naunyn-Schmiedeberg's Arch. exp. Path. Pharmak. 191, 87 (1939).
Holtz, P., u. G. Kroneberg: Naunyn-Schmiedeberg's Arch. exp. Path. Pharmak. 206, 150 (1949).
Holzbauer, M. F., and M. Vogt: J. Neurochem. 1, 8 (1956).
Jenney, E. H.: Fed. Proc. 13 370 (1954).
Nachtsheim, H.: Dtsch. med. Wschr. 1939, 168.
Orloff, M. J., H. L. Williams and C. C. Pfeiffer: Proc. Soc. exp. Biol. (N. Y.) 70, 254 (1949).
Paasonen, M. K., and M. Vogt: J. Physiol. (Lond.) 131, 617 (1956).
Pletscher, A.: Helv. physiol. pharmacol. Acta 14, C76 (1956).
Pletscher, A., P. A. Shore and B. B. Brodie: J. Pharmacol. exp. Ther. 116, 46, 84 (1956).
Toman, J. E. P., and L. S. Goodman: Res. Publ. Ass. nerv. ment. Dis. 26, 141 (1947)
Udenfriend, S., H. Weissbach and D. F. Bogdanski: J. biol. Chem. 224, 803 (1957).
Zeller, E. A., J. Barsky, J. R. Fouts, W. F. Kirchheimer and L. S. Van Orden: Experientia (Basel) 8, 349 (1952).
Author information
Authors and Affiliations
Additional information
Mit 1 Textabbildung
Rights and permissions
About this article
Cite this article
Kobinger, W. Beeinflussung der cardiazolkrampfschwelle durch veränderten 5-hydroxytryptamingehalt des zentralnervensystems. Naunyn - Schmiedebergs Arch 233, 559–566 (1958). https://doi.org/10.1007/BF00245842
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00245842